Global Biologics Market - Strategic Insights and Forecasts (2026-2031)

The global biologics market is projected to register a strong CAGR during the forecast period (2026-2031).

Market Overview

The need for biologics is linked less to general pharmaceutical volume and more to disease areas where biological mechanisms can offer targeted treatment, replace deficient proteins, modify immune responses, or address conditions with limited conventional options. Oncology, autoimmune disease, metabolic disorders, rare diseases, and infectious diseases therefore remain important sources of demand.

Clinical innovation is also changing the value structure of the market. Established biologics generate recurring demand through chronic treatment, while newer therapies can command higher value when they address severe disease or expand treatment into previously underserved populations. Roche reported 12 positive late-stage clinical readouts in 2025 across areas including breast cancer, multiple sclerosis, and lupus, illustrating continued investment in biologic and biologic-enabled treatment pipelines.

Purchasing decisions increasingly depend on clinical outcomes, administration frequency, manufacturing reliability, reimbursement, supply continuity, and evidence of value. Buyers also face a wider choice between reference biologics and biosimilars. The FDA continues to add biosimilars to the U.S. market, while the EMA has refined its approach to biosimilar development and interchangeability.

Manufacturing is becoming a larger strategic consideration because biologics require controlled processes, specialised facilities, validated production systems, and cold-chain or other tightly managed distribution conditions for many products. Capacity expansion by Samsung Biologics and Novo Nordisk illustrates how suppliers are committing capital to production, fill-finish, and supply-chain flexibility rather than relying only on existing capacity.

Key Market Indicators

Market Drivers

Expansion of targeted treatment in chronic and immune-mediated diseases. Biologics are increasingly used where disease mechanisms can be addressed through specific molecular or immune targets. AbbVie reported 2025 global revenue of $17.562 billion for Skyrizi and $8.304 billion for Rinvoq, showing the commercial scale that targeted immunology products can achieve. Sanofi also reported 32.2% growth in Dupixent sales in 2025. The resulting demand is not limited to new patients. Expanded indications can increase treatment pools and extend product use across related diseases.

Growing demand for treatments in oncology and difficult-to-treat diseases. Cancer remains a large source of biologic development because antibody therapies, bispecific molecules, cell therapies, and other biological approaches can target specific disease pathways. Amgen reported $8.7 billion in 2025 innovative oncology sales, with growth driven by its BiTE platform, while BLINCYTO sales reached $1.6 billion. Roche also reported late-stage progress across breast cancer and other serious diseases. These developments support demand for specialised biologics, but also raise the value placed on clinical differentiation and treatment outcomes.

Wider vaccine use and persistent immunization gaps. Vaccines remain a core biologics category because public health systems continue to fund routine immunization while adding products for new diseases and age groups. WHO reported that 85% of infants received three DTP-containing vaccine doses in 2025, yet 13.5 million children received no vaccination. HPV vaccine coverage among girls reached 33%, leaving a large gap against the 2030 target. These gaps support continued public procurement, manufacturing investment, and distribution expansion.

Expansion of biologics manufacturing and outsourced production. Drug developers increasingly use specialised manufacturing partners to obtain capacity, process expertise, and production flexibility. Samsung Biologics brought Plant 5 into operation in 2025, raising total capacity to 784,000 liters across five plants. The company also plans additional capacity and development services for multiple biologic modalities. This model supports smaller biotechnology companies that may lack commercial-scale facilities and allows established pharmaceutical companies to spread manufacturing requirements across internal and external networks.

Market Restraints and Challenges

Manufacturing complexity and long capacity lead times. Biologic production requires validated processes, controlled environments, specialised equipment, trained personnel, and strict quality systems. Capacity cannot be added as quickly as demand can change. Novo Nordisk identifies resource shortages, geopolitical instability, trade disputes, local manufacturing rules, and long lead times for capacity expansion as supply-chain risks. These constraints can increase capital needs and create exposure to production delays. They also encourage manufacturers to maintain multiple sites or suppliers, raising fixed costs and operational complexity.

Biosimilar competition is increasing pressure on mature products. Loss of exclusivity can change pricing and market-share conditions quickly when multiple biosimilar suppliers enter. Amgen states that biosimilar competition already affects its products in the U.S. and Europe and expects further pressure as additional competitors enter. European national reimbursement, tendering, and substitution policies can accelerate uptake. For originator manufacturers, the issue affects revenue and margins. For buyers, it creates additional treatment options, but procurement decisions still depend on clinical confidence, supply reliability, contracting, and local substitution rules.

Affordability and reimbursement can restrict access to high-cost biologics. Clinical value does not automatically translate into broad patient access. Public and private payers must balance treatment outcomes against healthcare budgets, particularly for chronic therapies that require long-term use. Novo Nordisk identifies affordability and access as continuing risks while expanding capacity for obesity and diabetes medicines. Lower realised prices, payer coverage decisions, and market-access agreements can reduce manufacturer revenue even when patient demand remains high. This creates pressure to prove economic value alongside clinical benefit.

Regulatory and quality requirements raise development and production costs. Biologics require detailed evidence on manufacturing consistency, safety, clinical performance, and post-market monitoring. The complexity increases further for cell and gene therapies, where manufacturing processes can be closely tied to product performance. Companies must also maintain inspection readiness across multiple sites and markets. Novo Nordisk reported 171 inspections in 2025, with several still in progress or awaiting final regulatory acceptance, illustrating the continuing operational burden associated with regulated biological production.

Major Segment Analysis

Monoclonal antibodies

Monoclonal antibodies represent a commercially important product category because they are used across oncology, autoimmune disease, inflammatory disorders, neurology, and other specialised indications. Their commercial model benefits from chronic treatment, expanded indications, and the ability to target defined biological pathways. AbbVie’s Skyrizi and Rinvoq revenues and Sanofi’s Dupixent performance demonstrate the revenue scale that established antibody products can achieve when supported by broad indications and strong clinical positioning.

Purchasing decisions for monoclonal antibodies extend beyond efficacy. Payers assess treatment cost, duration, administration, comparative outcomes, and biosimilar availability, while providers also consider dosing frequency, patient suitability, and supply continuity. Manufacturers therefore compete through clinical differentiation, new indications, formulation improvements, manufacturing capacity, and lifecycle management. The arrival of biosimilars adds another layer of price competition, particularly for mature antibodies with large treatment populations.

Regional Analysis

North America remains commercially important because of its large pharmaceutical base, high biologic adoption, extensive clinical development activity, and established reimbursement infrastructure. The U.S. FDA continues to approve new biologics and biosimilars, including interchangeable products. This supports product innovation while increasing competitive pressure on mature biologics. Canada also uses biosimilar policies to improve access and manage public drug budgets.

Europe combines strong biologic demand with a mature regulatory framework and active biosimilar adoption. EMA recommended 104 medicines for marketing authorisation in 2025, including 38 with new active substances. The agency also continues to refine biosimilar development rules, with a focus on reducing unnecessary clinical requirements while maintaining safety and quality standards. National reimbursement and tender systems create differences between individual European markets.

Asia Pacific is gaining importance through both demand and manufacturing. India recorded 97% DTP first-dose coverage and 95% third-dose hepatitis B coverage in the latest WHO/UNICEF estimates, while its regulator continues to publish vaccine manufacturing and import permissions. South Korea is also strengthening its role as a biologics manufacturing base through Samsung Biologics. These conditions support both domestic access and export-oriented production.

Middle East and Africa present a mixed market structure. Public vaccination programs and disease-control initiatives support demand, but access varies widely by country because of funding, healthcare infrastructure, cold-chain capacity, and manufacturing dependence. WHO data shows that global vaccination gaps remain concentrated among underserved populations, creating scope for public procurement and technology-transfer programs. South America also remains driven by public immunization programs and national healthcare procurement, with Brazil representing an important regional market.

Competitive Landscape

The competitive structure combines originator pharmaceutical companies, specialist biotechnology firms, biosimilar manufacturers, vaccine producers, and contract development and manufacturing organisations. Roche, Amgen, AbbVie, Novo Nordisk, Johnson & Johnson, Takeda, AstraZeneca, Merck, Eli Lilly, Sanofi, and UCB compete mainly through differentiated pipelines, clinical evidence, lifecycle expansion, manufacturing capacity, and access to large healthcare markets.

Samsung Biologics adds a different competitive model by supplying manufacturing capacity and development services rather than competing only through proprietary medicines. Its five-plant network and expanding service base increase the role of external manufacturing in the biologics value chain.

Competitive pressure is strongest where patents expire and biosimilars can enter. Amgen's 2025 biosimilar sales reached $3.0 billion, illustrating the commercial opportunity created by this segment. Originators are responding through new indications, formulation changes, pipeline replacement, acquisitions, and manufacturing investment.

Recent Developments

• July 2026: Johnson & Johnson completed its $1 billion acquisition of Firefly Bio, adding a degrader antibody conjugate platform targeting KRAS-driven cancers and strengthening next-generation oncology capabilities for difficult solid tumors.

• July 2026: argenx agreed to acquire Forte Biosciences, adding FB102, a first-in-class anti-CD122 antibody, strengthening its immunology pipeline for vitiligo, celiac disease, and other autoimmune conditions for immunology worldwide.

• July 2026: Novartis agreed to acquire Myricx Bio, gaining an NMTi antibody-drug conjugate payload platform designed to address resistance and expand next-generation oncology treatment possibilities across multiple cancer types.

• April 2026: The U.S. FDA approved Dupixent for children aged two to 11 with chronic spontaneous urticaria, expanding the addressable patient population for an established biologic. The EU approved the same pediatric indication earlier in April.

Regulatory and Policy Environment

Biologics face regulatory controls across discovery, clinical development, manufacturing, approval, distribution, and post-market monitoring. In the U.S., the FDA maintains separate regulatory pathways for biologics and biosimilars, with additional requirements for products seeking interchangeable status. The agency's current biosimilar database shows continued approvals in 2026, including products referencing established biologics such as Prolia, Lucentis, Simponi, Neupogen, and Novolog.

Europe has a mature centralised framework for biological medicines and biosimilars. EMA and the Heads of Medicines Agencies have confirmed that EU-approved biosimilars can be considered interchangeable with their reference products or equivalent biosimilars, subject to national implementation. EMA is also pursuing a more efficient development model that could reduce clinical data requirements for some biosimilars while retaining quality and safety standards.

Vaccines remain closely tied to government policy because national immunization programs determine procurement volumes, eligible populations, schedules, and public funding. WHO's 2025 data shows both broad coverage and persistent gaps, placing continued emphasis on routine immunization, catch-up programs, HPV vaccination, and equitable access. National regulators such as India's CDSCO also maintain detailed controls over vaccine manufacturing and import permissions.

Outlook and Strategic Implications

The 2026-2031 period is likely to be shaped by the interaction between clinical innovation, access, biosimilar competition, and manufacturing capacity. Demand should remain strongest where biologics address chronic diseases, serious cancers, immune disorders, metabolic conditions, rare diseases, and unmet infectious-disease needs. Product success will depend increasingly on the ability to combine clinical differentiation with manageable treatment cost and dependable supply.

Manufacturing decisions will have a direct effect on competitive performance. Companies with flexible capacity, qualified suppliers, multi-site production, and strong quality systems will be better positioned to absorb demand changes and reduce supply disruption. The expansion of Samsung Biologics and Novo Nordisk shows that capacity is being treated as a strategic asset rather than only a production expense.

For originator companies, the central commercial challenge will be replacing revenue affected by patent expiry while expanding newer products into additional indications. For biosimilar manufacturers, regulatory clarity and payer acceptance will determine how quickly competition converts into volume. For CDMOs and technology suppliers, demand will depend on the number of products moving from clinical development into commercial production. Regulators and public purchasers will continue to balance innovation, supply security, quality, and affordability. The market's performance through 2031 will therefore depend not only on the number of new biologics reaching approval, but also on whether healthcare systems can finance their use and whether manufacturers can produce them at the required scale and quality.

Global Biologics Market Scope: